|
|
Vaccine Detail
|
P53-Synthetic Long Peptides Vaccine |
| Vaccine Information |
- Vaccine Name: P53-Synthetic Long Peptides Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007134
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: p53
- TP53
gene engineering:
- Preparation: Peptides were dissolved in dimethyl sulfoxide admixed with 20 mM phosphate buffer (pH 7.5) and emulsified with an equal volume of Montanide ISA-51 (Dijkgraaf et al., 2015).
- Description: This is for Ovarian Cancer(NCT00844506). A peptide vaccine consisting of 10 synthetic long peptides (SLPs), 25-30 amino acids in size and derived from the middle portion of p53 (amino acids 70-251), mixed with the adjuvant Montanide ISA-51 with potential immunostimulatory and antitumor activities. Upon administration, p53 synthetic long peptide (70-251) vaccine may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL) response against p53-expressing tumor cells. p53, a tumor associated antigen (TAA), may be overexpressed in variety of cancer cell types (NCIT_C82420). p53 SLP vaccine consisted of 9 synthetic 25–30 amino acids long overlapping peptides, spanning amino acids 70–235 of the wt-p53 protein (Dijkgraaf et al., 2015).
|
| Host Response |
|
|
| References |
Dijkgraaf et al., 2015: Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VT, Daemen TA, van der Hoeven JJ, Melief CJ, Welters MJ, Kroep JR, van der Burg SH. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget. 2015; 6(31); 32228-32243. [PubMed: 26334096].
NCIT_C82420: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82420]
NCT00844506: [https://clinicaltrials.gov/ct2/show/NCT00844506?term=P53-Synthetic+Long+Peptides+Vaccine&rank=1]
Schuler et al., 2014: Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, Argiris A, Gooding W, Butterfield LH, Whiteside TL, Ferris RL. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014; 20(9); 2433-2444. [PubMed: 24583792].
|
|
